Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nao Jonai

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Communications Medicine|March 31, 2026
Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trialsShunsuke Hamada, Miharu Suda, Katsuyasu Ishida, et al.
Nucleosides, Nucleotides & Nucleic Acids|January 17, 2026
Design, synthesis, and biological properties of novel metabolizable pH-responsive lipids for use in lipid nanoparticles for siRNA delivery and mRNA vaccinationTakako Niwa, Yoshiyuki Onishi, Masakazu Tamura, et al.
Vaccine|August 16, 2023
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical studyKaoru Toyama, Takashi Eto, Kenji Takazawa, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2009
Target identification using drug affinity responsive target stability (DARTS)Brett Lomenick, Rui Hao, Nao Jonai, et al.
Nature Biotechnology|June 29, 2010
Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligaseMariam Aghajan, Nao Jonai, Karin Flick, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Communications Medicine|March 31, 2026
Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trialsShunsuke Hamada, Miharu Suda, Katsuyasu Ishida, et al.
Nucleosides, Nucleotides & Nucleic Acids|January 17, 2026
Design, synthesis, and biological properties of novel metabolizable pH-responsive lipids for use in lipid nanoparticles for siRNA delivery and mRNA vaccinationTakako Niwa, Yoshiyuki Onishi, Masakazu Tamura, et al.
Vaccine|August 16, 2023
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical studyKaoru Toyama, Takashi Eto, Kenji Takazawa, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2009
Target identification using drug affinity responsive target stability (DARTS)Brett Lomenick, Rui Hao, Nao Jonai, et al.
Nature Biotechnology|June 29, 2010
Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligaseMariam Aghajan, Nao Jonai, Karin Flick, et al.
Pageof 1